Liaoning Chengda Biotechnology Co. Ltd. A
Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company's rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant h… Read more
Liaoning Chengda Biotechnology Co. Ltd. A (688739) - Net Assets
Latest net assets as of June 2025: CN¥9.36 Billion CNY
Based on the latest financial reports, Liaoning Chengda Biotechnology Co. Ltd. A (688739) has net assets worth CN¥9.36 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.79 Billion) and total liabilities (CN¥431.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥9.36 Billion |
| % of Total Assets | 95.59% |
| Annual Growth Rate | 22.79% |
| 5-Year Change | 132.2% |
| 10-Year Change | N/A |
| Growth Volatility | 49.19 |
Liaoning Chengda Biotechnology Co. Ltd. A - Net Assets Trend (2019–2024)
This chart illustrates how Liaoning Chengda Biotechnology Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Liaoning Chengda Biotechnology Co. Ltd. A (2019–2024)
The table below shows the annual net assets of Liaoning Chengda Biotechnology Co. Ltd. A from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥9.56 Billion | -0.38% |
| 2023-12-31 | CN¥9.60 Billion | -0.52% |
| 2022-12-31 | CN¥9.65 Billion | +3.18% |
| 2021-12-31 | CN¥9.35 Billion | +127.09% |
| 2020-12-31 | CN¥4.12 Billion | +20.24% |
| 2019-12-31 | CN¥3.42 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Liaoning Chengda Biotechnology Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 90.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.05 Billion | 42.39% |
| Other Components | CN¥5.51 Billion | 57.61% |
| Total Equity | CN¥9.56 Billion | 100.00% |
Liaoning Chengda Biotechnology Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Liaoning Chengda Biotechnology Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GLAD.L. CUM.PFD SER.B
F:1NF
|
$602.40 Million |
|
Puyang Refractories Group Co Ltd
SHE:002225
|
$602.85 Million |
|
Arvinas Inc
NASDAQ:ARVN
|
$603.03 Million |
|
Heritage Insurance Hldgs Inc
NYSE:HRTG
|
$603.45 Million |
|
Sercomm Corp
TW:5388
|
$602.02 Million |
|
GCS Holdings
TWO:4991
|
$601.84 Million |
|
WEB Travel Group Ltd
AU:WEB
|
$601.69 Million |
|
Power HF Co Ltd
SHG:605100
|
$601.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Liaoning Chengda Biotechnology Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,599,129,240 to 9,562,467,951, a change of -36,661,289 (-0.4%).
- Net income of 342,821,554 contributed positively to equity growth.
- Dividend payments of 329,381,581 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥342.82 Million | +3.59% |
| Dividends Paid | CN¥329.38 Million | -3.44% |
| Other Changes | CN¥-50.10 Million | -0.52% |
| Total Change | CN¥- | -0.38% |
Book Value vs Market Value Analysis
This analysis compares Liaoning Chengda Biotechnology Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.12x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.81x to 1.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥9.14 | CN¥25.68 | x |
| 2020-12-31 | CN¥10.99 | CN¥25.68 | x |
| 2021-12-31 | CN¥22.46 | CN¥25.68 | x |
| 2022-12-31 | CN¥23.17 | CN¥25.68 | x |
| 2023-12-31 | CN¥23.05 | CN¥25.68 | x |
| 2024-12-31 | CN¥22.96 | CN¥25.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Liaoning Chengda Biotechnology Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.45%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.05x
- Recent ROE (3.59%) is below the historical average (11.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 20.39% | 41.65% | 0.45x | 1.09x | CN¥355.89 Million |
| 2020 | 22.30% | 46.01% | 0.44x | 1.09x | CN¥506.38 Million |
| 2021 | 9.54% | 42.74% | 0.21x | 1.05x | CN¥-42.71 Million |
| 2022 | 7.40% | 39.34% | 0.18x | 1.04x | CN¥-250.94 Million |
| 2023 | 4.85% | 26.62% | 0.17x | 1.05x | CN¥-493.99 Million |
| 2024 | 3.59% | 20.45% | 0.17x | 1.05x | CN¥-613.43 Million |
Industry Comparison
This section compares Liaoning Chengda Biotechnology Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,249,192,405
- Average return on equity (ROE) among peers: 10.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Liaoning Chengda Biotechnology Co. Ltd. A (688739) | CN¥9.36 Billion | 20.39% | 0.05x | $602.31 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $85.28 Million | -13.04% | 0.97x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $687.82 Million | 11.47% | 1.00x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $134.48 Million | 10.88% | 3.14x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $915.76 Million | -0.65% | 0.06x | $253.71 Million |
| Chengzhi Shareholding Co Ltd (000990) | $997.75 Million | 5.11% | 1.23x | $934.96 Million |
| Hualan Biological EngineeringInc (002007) | $6.88 Billion | 18.64% | 0.10x | $1.99 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $7.66 Billion | 47.23% | 0.35x | $793.09 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $31.94 Billion | 6.87% | 0.05x | $3.75 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $403.60 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.14 Billion | 14.05% | 0.13x | $344.80 Million |